Prama Ghosh, Amity University Kolkata
Past information has shown that patients with type 2 diabetes would by and large lean toward fewer injections and more prominent adaptability than is typical of the current once-daily insulin treatment. Therefore, decreasing the number of injections might build acknowledgment of and adherence to insulin treatment among patients with type 2 diabetes, thereby improving glycemic control. Insulin icodec is a basal insulin analog intended for once-weekly administration that is being developed for the treatment of diabetes.
A 26-week randomized phase 2 trial on 247 patients with type 2 diabetes was conducted to find out the efficacy and safety of once-weekly icodec as compared to once-daily glargine U100. It was seen there was no between-group contrast related to the key adverse effects of insulin.
Glucose – lowering efficacy and safety profile in patients with type 2 diabetes is the same for both once-weekly insulin icodec and once-daily glargine U100.
Source:
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment,
Julio Rosenstock, M.D., Harpreet S. Bajaj, M.D., M.P.H., Andrej Janež, M.D., PhD,Robert Silver, M.D., Kamilla Begtrup, M.Sc., Melissa V. Hansen, M.D., PhD,Ting Jia, M.D., Ph.D., and Ronald Goldenberg, M.D.for the NN1436-4383 Investigators
https://www.nejm.org/doi/full/10.1056/NEJMoa2022474
For more updates, please visit https://bioxone.in//https://bioxone.in//
A GREAT MANUFACTURING INNOVATION BY OXGENE
Subhangi Das, Bankura Sammilani College OXGENE has developed scalable gene therapy technology, marking the day as the launch of its scalable, plasmid-free technical system for AAV. OXGENE ‘s new TESSA technology is a great illustration of the change in AAV manufacturing. Adeno associated virus or AAV having benefits such as low immunogenicity and a favorable […]